FGF23 and bone metastasis: In patients with cancer and bone metastases from solid tumors, elevated serum levels of FGF23 were associated with shorter survival, as well as time to skeletal-related events (43), providing the first evidence of the prognostic significance of FGF23 in individuals with bone metastasis.